Armata Pharmaceuticals Inc (ARMP)
:ARMP
ARMP Stock Chart & Stats
$9.35
$0.11(5.39%)
At close: 4:00 PM EST
$9.35
$0.11(5.39%)
Day’s Range― - ―
52-Week Range$0.90 - $16.34
Previous CloseN/A
Volume48.90K
Average Volume (3M)536.86K
Market Cap
$342.52M
Enterprise Value$362.81M
Total Cash (Recent Filing)$8.69M
Total Debt (Recent Filing)$31.10M
Price to Earnings (P/E)―
Beta0.72
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.42
Shares Outstanding36,406,906
10 Day Avg. Volume121,090
30 Day Avg. Volume536,864
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue56.00
Enterprise Value/Gross Profit72.56
Enterprise Value/Ebitda-6.18
Forecast
1Y Price Target
$15.00Price Target Upside60.43% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.09
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2a diSArm results showed AP-SA02 added to standard antibiotics produced substantially better clinical responses with no relapse or treatment failure, supporting the expectation that a confirmatory Phase 3 could demonstrate superiority in difficult Staphylococcus aureus bloodstream infections.
Manufacturing Readiness And First-mover AdvantageA newly commissioned in-house cGMP phage manufacturing facility with successful initial production runs provides operational readiness to support pivotal trials, enables consistent supply of intravenous phage cocktails, and strengthens a potential first-mover position among bacteriophage developers.
Regulatory EndorsementWritten FDA feedback and potential Qualified Infectious Disease Product status support advancing AP-SA02 into a superiority Phase 3 study and could enable priority review and additional market exclusivity if granted.
Bears Say
Analytic Conflict Of InterestBusiness relationships between the covering firm and the company may create perceived conflicts that could undermine confidence in analyst reports and negatively influence investor sentiment.
Execution Risk For Trial InitiationInitiation of the pivotal Phase 3 depends on completing regulatory, manufacturing, and operational milestones, so delays or failures in any of these areas could postpone the trial and raise development risk.
Funding And Dilution RiskLimited cash resources increase the likelihood that additional financing will be required to advance Phase 3 and other programs, creating dilution risk for existing shareholders if capital is raised.
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $0.90 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $342.52M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2026 which is in 40 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Mar 25, 2026. The company reported -$3.42 earnings per share for the quarter, missing the consensus estimate of -$0.28 by -$3.14.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,406,906 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$3.42 in its last earnings report, missing expectations of -$0.28. Following the earnings report the stock price went up 8.595%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.00 (60.43% Upside)
$15.00 (60.43% Upside)
Blogger Sentiment
Bearish
ARMP Sentiment 100%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.55%
12-Months-Change
Fundamentals
Return on Equity
70.29%
Trailing 12-Months
Asset Growth
-8.88%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
ARMP Stock 12 Month Forecast
Average Price Target
$15.00
▲(60.43% Upside)
Technical Analysis
Ownership Overview
0.63% Insiders
1.19% Mutual Funds
1.08% Other Institutional Investors
96.16% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---